Fortitude Family Office’s Heron Therapeutics HRTX Stock Holding History

Fortitude Family Office’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$379	Buy	+888	New	+$712	﹤0.01%	2019
2026 Q1	–	Sell	-79	Closed	-$103	–	1975
2025 Q4	$103	Sell	79 -10	-11%	-$12	﹤0.01%	1892
2025 Q3	$112	Hold	89	–	–	﹤0.01%	1953
2025 Q2	$184	Sell	89 -192	-68%	-$392	﹤0.01%	1970
2025 Q1	$618	Hold	281	–	–	﹤0.01%	1071
2024 Q4	$430	Hold	281	–	–	﹤0.01%	1227
2024 Q3	$559	Hold	281	–	–	﹤0.01%	1156
2024 Q2	$984	Hold	281	–	–	﹤0.01%	883
2024 Q1	$778	Hold	281	–	–	﹤0.01%	913
2023 Q4	$478	Buy	+281	New	+$309	﹤0.01%	976

Other funds holding HRTX

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Fortitude Family Office's HRTX Position: Q2 2026 in Review

Fortitude Family Office opened a new position in Heron Therapeutics (HRTX) in Q2 2026: 888 shares worth $379. The stake represents ﹤0.01% of the portfolio and ranks #2019 among its holdings. This is a return to the name: Fortitude Family Office previously reported a position in HRTX as recently as Q4 2025.

Fortitude Family Office first reported a position in HRTX in Q4 2023 and has held it in 10 quarters since. The position peaked at $984 in Q2 2024. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

Fortitude Family Office held 888 shares of Heron Therapeutics worth $379 as of Q2 2026.
Heron Therapeutics was a new Fortitude Family Office position in Q2 2026.
Heron Therapeutics made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #2019 holding.
Fortitude Family Office first reported a position in Heron Therapeutics in Q4 2023 and has held it in 10 quarters since.
Fortitude Family Office's Heron Therapeutics position peaked at $984 in Q2 2024.
163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.